论文部分内容阅读
目的探索肝硬化患者血清中胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)及胃泌素-17(G-17)的水平变化及临床意义。方法选取自2013年7月至2014年11月我院接收的肝硬化患者97例,作为观察组;另选取同期未患胃病的肝硬化患者92例,作为对照组。采用ELISA法分析肝硬化患者血清中PGⅠ、PGⅡ及G-17的水平变化。结果与对照组相比,观察组患者血清中PGⅠ、PGⅡ和G-17水平明显高于对照组,且差异具有统计学意义(P<0.05)。另外,与Child-Paugh A级相比,Child-Paugh C级患者血清中PGⅠ、PGⅡ和G-17的水平显著升高;Child-Paugh B级患者血清中PGⅠ和G-17的水平明显升高,差异具有统计学意义(P<0.05)。结论肝硬化患者血清中PGⅠ、PGⅡ及G-17可以作为指标来表征胃部疾病,且三个指标的水平与Child-Paugh分级有一定的联系。
Objective To explore the changes and clinical significance of serum levels of PG Ⅰ, PG Ⅱ and G-17 in patients with cirrhosis. Methods Ninety-seven patients with cirrhosis received in our hospital from July 2013 to November 2014 were selected as the observation group. Another 92 patients with cirrhosis who did not have stomach disease during the same period were selected as the control group. Serum levels of PGⅠ, PGⅡ and G-17 in patients with cirrhosis were analyzed by ELISA. Results Compared with the control group, the serum levels of PGⅠ, PGⅡ and G-17 in the observation group were significantly higher than those in the control group, and the difference was statistically significant (P <0.05). In addition, serum levels of PGI, PGII and G-17 were significantly increased in Child-Paugh C patients compared with Child-Paugh A patients, and PGI and G-17 levels were significantly elevated in Child-Paugh B patients , The difference was statistically significant (P <0.05). Conclusion Serum levels of PGⅠ, PGⅡ and G-17 in patients with cirrhosis can be used as indicators to characterize gastric diseases, and the levels of these three indicators are correlated with Child-Paugh classification.